Gender differences and their effects on survival outcomes in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors: A systematic review and meta-analysis

Resource type: Publication Publication
  • Authors
    Madala S.; Rasul R.; Singla K.; Sison C.P.; Seetharamu N.; Castellanos M.R.
  • Type
    Original research
  • Journal
    Clinical Oncology
  • Publication Date
    2022
  • Abstract
    Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors have had a major impact on the approach to care of patients with lung cancer. An important issue that is not known is whether they benefit men and women the same. We conducted a meta-analysis of all randomised controlled trials evaluating PD-1/PD-L1 inhibition in patients with non-small cell lung cancer (NSCLC) to determine if clinical response and survival are influenced by gender.
Access Publication